2023
DOI: 10.3390/ph16010094
|View full text |Cite
|
Sign up to set email alerts
|

The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy

Abstract: DNA topoisomerase II (Top2) is essential for all eukaryotic cells in the regulation of DNA topology through the generation of temporary double-strand breaks. Cancer cells acquire enhanced Top2 functions to cope with the stress generated by transcription and DNA replication during rapid cell division since cancer driver genes such as Myc and EZH2 hijack Top2 in order to realize their oncogenic transcriptomes for cell growth and tumor progression. Inhibitors of Top2 are therefore designed to target Top2 to trap … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
7
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(7 citation statements)
references
References 139 publications
0
7
0
Order By: Relevance
“…The Z-DNA related properties of topoII described in this publication, potentially shared with some of its interactome partners [ 140 ], offer the prospect of new antiproliferative compounds, pharmacologically complementary to the numerous existing anticancer drugs targeting the isomerase mechanism of the protein. Current strategies for topoII-based drug discovery [ 56 , 57 , 58 , 141 , 142 ] lend themselves to this goal. GTP-binding site-specific compounds based on non-hydrolyzable nucleotides, isomerase inhibitory purine scaffolds [ 143 ] or suitably adapted ATP-competitors [ 144 ] would introduce a new dimension of target selectivity.…”
Section: Resultsmentioning
confidence: 99%
“…The Z-DNA related properties of topoII described in this publication, potentially shared with some of its interactome partners [ 140 ], offer the prospect of new antiproliferative compounds, pharmacologically complementary to the numerous existing anticancer drugs targeting the isomerase mechanism of the protein. Current strategies for topoII-based drug discovery [ 56 , 57 , 58 , 141 , 142 ] lend themselves to this goal. GTP-binding site-specific compounds based on non-hydrolyzable nucleotides, isomerase inhibitory purine scaffolds [ 143 ] or suitably adapted ATP-competitors [ 144 ] would introduce a new dimension of target selectivity.…”
Section: Resultsmentioning
confidence: 99%
“…TOP2A is an enzyme involved in DNA replication and transcription, and its overexpression has been associated with a poor prognosis in NSCLC patients 39,40 . In addition, several TOP2A inhibitors, such as etoposide and doxorubicin, have shown promising results in preclinical studies for cancer treatment 41 . TYMS is an important enzyme for making DNA.…”
Section: Discussionmentioning
confidence: 99%
“… 39 , 40 In addition, several TOP2A inhibitors, such as etoposide and doxorubicin, have shown promising results in preclinical studies for cancer treatment. 41 TYMS is an important enzyme for making DNA. It has been found to be upregulated in NSCLC and could be a target for chemotherapy drugs like 5‐fluorouracil.…”
Section: Discussionmentioning
confidence: 99%
“…Inhibiting topoisomerase II can lead to DNA damage and cell death in cancer cells. This is a mechanism used by several chemotherapeutic drugs [ 48 , 49 ]. Trans-syringin exhibits a high affinity for topoisomerase II, indicating its potential to effectively inhibit the activity of this enzyme.…”
Section: Discussionmentioning
confidence: 99%